Oncodriver expression may differ according to etiology as non-hereditary DCIS lesions express more HER2 while BRCA mutation carriers express HER3 and C-MET in DCIS, suggesting targeting a single oncodriver may not be sufficient for prevention of all DCIS. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.